SenesTech (SNES) 10-Q 9 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 08, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-37941
Entity Registrant Name	SENESTECH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2079805
Entity Address, Address Line One	23460 N 19th Ave,
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Phoenix
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85027
City Area Code	(928)
Local Phone Number	779-4143
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SNES
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		3,631,060
Entity Central Index Key	0001680378
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,145	$ 4,775
Accounts receivable, net	83	113
Prepaid expenses	385	378
Inventory, net	703	853
Total current assets	3,316	6,119
Right to use assets, operating leases	217	347
Property and equipment, net	313	294
Other noncurrent assets	22	22
Total assets	3,868	6,782
Current liabilities:
Accounts payable	147	540
Accrued expenses	671	560
Current portion of operating lease liability	192	180
Current portion of note payable	9	0
Deferred revenue	15	44
Total current liabilities	1,034	1,324
Operating lease liability, less current portion	34	179
Note payable, less current portion	44	0
Total liabilities	1,112	1,503
Commitments and contingencies (see notes)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized, 5,899,060 shares issued and 3,279,485 shares outstanding as of September 30, 2023 and 809,648 shares issued and outstanding as of December 31, 2022	3	1
Additional paid-in capital	130,933	127,481
Accumulated deficit	(128,180)	(122,203)
Total stockholders’ equity	2,756	5,279
Total liabilities and stockholders’ equity	$ 3,868	$ 6,782

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	5,899,060	809,648
Common stock, shares outstanding (in shares)	3,279,485	809,648

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenues, net	$ 360	$ 250	$ 898	$ 722
Cost of sales	184	128	488	374
Gross profit	176	122	410	348
Operating expenses:
Research and development	379	452	1,147	1,399
Selling, general and administrative	1,748	2,289	5,259	6,473
Total operating expenses	2,127	2,741	6,406	7,872
Loss from operations	(1,951)	(2,619)	(5,996)	(7,524)
Other income (expense):
Interest income	4	1	19	4
Interest expense	0	0	0	(1)
Miscellaneous expense, net	0	(28)	0	(26)
Other income (expense), net	4	(27)	19	(23)
Net loss	(1,947)	(2,646)	(5,977)	(7,547)
Comprehensive loss	$ (1,947)	$ (2,646)	$ (5,977)	$ (7,547)
Weighted average shares outstanding - basic (in shares)	4,176,592	610,648	3,037,790	610,578
Weighted average shares outstanding - diluted (in shares)	4,176,592	610,648	3,037,790	610,578
Net loss per share - basic (in dollars per share)	$ (0.47)	$ (4.33)	$ (1.97)	$ (12.36)
Net loss per share - diluted (in dollars per share)	$ (0.47)	$ (4.33)	$ (1.97)	$ (12.36)

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (5,977)	$ (7,547)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	104	148
Stock-based compensation	467	570
Bad debt expense	(4)	5
Loss on sale of property and equipment	0	28
Changes in operating assets and liabilities:
Accounts receivable	34	(16)
Prepaid expenses	(7)	(174)
Inventory	150	48
Other assets	(3)	0
Accounts payable	(393)	142
Accrued expenses	111	409
Deferred revenue	(29)	48
Net cash used in operating activities	(5,547)	(6,339)
Cash flows from investing activities:
Purchase of property and equipment	(114)	(167)
Proceeds received from sale of property and equipment	0	4
Net cash used in investing activities	(114)	(163)
Cash flows from financing activities:
Proceeds from issuances of common stock, net	2,998	0
Proceeds from (repayments of) notes payable, net	44	(5)
Repayments of finance lease obligations	0	(27)
Payment of employee withholding taxes related to share based awards	(11)	0
Net cash provided by (used in) financing activities	3,031	(32)
Decrease in cash and cash equivalents	(2,630)	(6,534)
Cash and cash equivalents, beginning of period	4,775	9,326
Cash and cash equivalents, end of period	2,145	2,792
Supplemental cash flow information is as follows:
Cash paid for interest	0	1
Cash paid for income taxes	0	0
Non-cash investing and financing activities:
Note payable incurred for the purchase of certain equipment	$ 10	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Nature of Business SenesTech, Inc. (subsequently referred to in this report as “we,” “us,” “our,” or “our company”) was incorporated in the state of Nevada in July 2004. On November 12, 2015, we subsequently reincorporated in the state of Delaware. Our corporate headquarters and manufacturing site are in Phoenix, Arizona. We have developed and are commercializing a global, proprietary technology for managing animal pest populations, initially rat populations, through fertility control. Our first product is known as ContraPest ® . ContraPest is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide. ContraPest limits reproduction of male and female rats beginning with the first breeding cycle following consumption. ContraPest is being marketed for use in controlling Norway and roof rat populations. In addition to the U.S. Environmental Protection Agency registration of ContraPest, we must obtain registration from the various state regulatory agencies prior to selling in each state. To date, we have received registration for ContraPest in all 50 states and the District of Columbia, 49 of which have approved the removal of the Restricted Use designation, as well as the District of Columbia and five major U.S. territories. We are pursuing additional products including Evolve TM , a soft bait containing the active ingredient cottonseed oil. Evolve limits reproduction of male and female rats after one to two breeding cycles following consumption. Evolve is being developed as a minimum risk pesticide under the U.S. Environmental Protection Agency Federal Insecticide, Fungicide, and Rodenticide Act, Section 25(b). For further information see Note 10. Going Concern Our condensed financial statements as of September 30, 2023 were prepared under the assumption that we would continue as a going concern. The reports of our independent registered public accounting firm that accompanies our financial statements for each of the years ended December 31, 2022 and December 31, 2021 contain a going concern qualification in which such firm expressed substantial doubt about our ability to continue as a going concern, based on the financial statements at that time. Specifically, we have incurred operating losses since our inception, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. These prior losses and expected future losses have had, and will continue to have, an adverse effect on our financial condition. If we encounter continued issues or delays in the commercialization of fertility control products, our expected future losses could have an adverse effect on our financial condition and negatively impact our ability to fund continued operations, obtain additional financing in the future and continue as a going concern. There are no assurances that such financing, if necessary, will be available to us at all or will be available in sufficient amounts or on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to generate additional funds in the future through additional financings, sales of our products, licensing fees, royalty payments or from other sources or transactions, we will exhaust our resources and will be unable to continue operations. Liquidity and Capital Resources Since our inception, we have sustained significant operating losses in the course of our research and development and commercialization activities and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under a former license agreement. We have primarily funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock. We have also raised capital through debt financing, consisting primarily of convertible notes and government loan programs, and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees. As of September 30, 2023, we had an accumulated deficit of $128.2 million and cash and cash equivalents of $2.1 million. Our ultimate success depends upon the outcome of a combination of factors, including the following: (i) successful commercialization of fertility control products and maintaining and obtaining regulatory approval of our products and product candidates; (ii) market acceptance, commercial viability and profitability of fertility control products and other products; (iii) the ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) the ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs. Based upon our current operating plan, we expect that cash and cash equivalents at September 30, 2023, in combination with anticipated revenue and any additional sales of our equity securities, will be sufficient to fund our current operations for at least the next three months. While we have evaluated and continue to evaluate our operating expenses and concentrate our resources toward the successful commercialization of fertility control products in the United States, additional financing will be needed before achieving anticipated revenue targets and margin targets. If we are unable to raise necessary capital through the sale of our securities, we may be required to take other measures that could impair our ability to be successful and operate as a going concern. In any event, additional capital is needed in order to fund our operating losses and research and development activities before we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts or discontinue operations. Condensed Financial Statements Our accompanying unaudited condensed financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with the U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In our opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly our financial position as of September 30, 2023, and our operating results and cash flows for the three- and nine-month periods ended September 30, 2023 and 2022. The accompanying financial information as of December 31, 2022 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 17, 2023. Recent Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our condensed financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in our financial statements include the valuation of inventory, common stock warrants, and stock-based awards, such as stock options and restricted stock units. Actual results could differ from such estimates. Comprehensive Loss We have no other comprehensive income items for the periods presented. As a result, our net loss and comprehensive loss were the same for the periods presented and a separate statement of comprehensive loss is not included in the accompanying condensed financial statements. Reclassification To conform with the 2023 presentation, we have reclassified the Loss on sale of property and equipment of $28,000 and Proceeds received from sale of property and equipment of $4,000 from Purchases of property and equipment in the condensed statement of cash flows for the nine months ended September 30, 2022. These reclassifications had no impact on our condensed statement of operations and comprehensive loss for the nine months ended September 30, 2022.

BALANCE SHEET COMPONENTS

BALANCE SHEET COMPONENTS	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET COMPONENTS	BALANCE SHEET COMPONENTS Cash and Cash Equivalents Highly liquid investments with maturities of three months or less as of the date of acquisition are classified as cash equivalents, of which we had $2.1 million and $4.8 million as of September 30, 2023 and December 31, 2022, respectively, included within cash and cash equivalents in the condensed balance sheets. Accounts Receivable, Net Accounts receivable, net consisted of the following (in thousands): September 30, December 31, Accounts receivable $ 85 $ 119 Allowance for uncollectible accounts (2) (6) Accounts receivable, net $ 83 $ 113 The following was the activity in the allowance for uncollectible accounts (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Balance as of beginning of period $ 4 $ 12 $ 6 $ — Increase in provision 2 — 2 12 Amounts written off, less recoveries (4) (7) (6) (7) Balance as of end of period $ 2 $ 5 $ 2 $ 5 Inventory, net Inventory, net consisted of the following (in thousands): September 30, December 31, Raw materials $ 670 $ 772 Work in progress 5 — Finished goods 46 99 Total inventory 721 871 Less: reserve for obsolescence (18) (18) Inventory, net $ 703 $ 853 The following was the activity in the reserve for obsolescence (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Balance as of beginning of period $ 18 $ 22 $ 18 $ 29 Increase in reserve — — — — Amounts relieved — (3) — (10) Balance as of end of period $ 18 $ 19 $ 18 $ 19 Prepaid Expenses Prepaid expenses consisted of the following (in thousands): September 30, December 31, Software licenses 138 157 Professional services 95 41 Insurance 44 61 Patents 17 39 Marketing programs and conferences 6 74 Other 85 6 Total prepaid expenses $ 385 $ 378 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): September 30, December 31, Research and development equipment $ 1,621 $ 1,558 Office and computer equipment 808 800 Autos 54 54 Furniture and fixtures 41 41 Leasehold improvements 119 119 Total in service 2,643 2,572 Accumulated depreciation and amortization (2,387) (2,283) Total in service, net 256 289 Construction in progress 57 5 Property and equipment, net $ 313 $ 294 Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, December 31, Compensation, severance and related benefits $ 521 $ 497 Legal services 135 36 Product warranty 15 18 Personal property and franchise tax — 6 Other — 3 Total accrued expenses $ 671 $ 560 Note Payable In August 2023, we arranged financing for the purchase of certain equipment. The note payable has an annual interest rate of 9.1% with a term of 5 years and is secured by the underlying equipment. As of September 30, 2023, future principal payments were as follows (in thousands): 2023 $ 3 2024 9 2025 10 2026 11 2027 12 Thereafter 8 Total principal payments 53 Less: current portion of note payable (9) Note payable, less current portion $ 44

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTSThe carrying amounts of our financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities. Note payable is recorded at amortized cost, which approximates fair value.

LEASES

LEASES	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
LEASES	LEASES We have operating leases for our corporate headquarters and our manufacturing and research facility, which expire in 2024. We were obligated under finance leases for certain research and computer equipment, of which the last arrangement expired in June 2022. The components of lease cost were as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Operating lease cost $ 55 $ 55 $ 166 $ 167 Finance lease cost: Amortization of right-of-use asset $ — $ — $ — $ 27 Interest on lease liability — — — 1 Total finance lease cost $ — $ — $ — $ 28 As of September 30, 2023, maturities of operating lease liabilities were as follows (in thousands): 2023 $ 50 2024 186 Total operating lease payments 236 Less: imputed interest (10) Total operating lease liabilities $ 226
LEASES	LEASES We have operating leases for our corporate headquarters and our manufacturing and research facility, which expire in 2024. We were obligated under finance leases for certain research and computer equipment, of which the last arrangement expired in June 2022. The components of lease cost were as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Operating lease cost $ 55 $ 55 $ 166 $ 167 Finance lease cost: Amortization of right-of-use asset $ — $ — $ — $ 27 Interest on lease liability — — — 1 Total finance lease cost $ — $ — $ — $ 28 As of September 30, 2023, maturities of operating lease liabilities were as follows (in thousands): 2023 $ 50 2024 186 Total operating lease payments 236 Less: imputed interest (10) Total operating lease liabilities $ 226

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION In 2018, our stockholders approved the adoption of the SenesTech, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan has since been amended and restated on certain occasions, most recently on June 26, 2023, when our stockholders approved an increase to the total number of authorized shares to 848,614 shares. Stock options are generally issued with a per share exercise price equal to the fair market value of our common stock at the date of grant. Options granted generally vest immediately, or ratably over a 12- to 36-month period coinciding with their respective service periods, with terms generally of five years. Certain stock option awards provide for accelerated vesting upon a change in control. As of September 30, 2023, we had 496,330 shares of common stock available for issuance under the 2018 Plan. Stock Options The following table presents the outstanding stock option activity: Number of Options Weighted Weighted Three months ended September 30, 2023: Outstanding as of June 30, 2023 479,426 $ 17.11 4.4 Granted — — — Exercised — — — Forfeited (30,750) 5.25 — Expired — — — Outstanding as of September 30, 2023 448,676 (1) 10.34 4.2 Nine months ended September 30, 2023: Outstanding as of December 31, 2022 280,810 17.00 3.9 Granted 199,421 1.25 5.0 Exercised — — — Forfeited (31,183) 17.97 — Expired (372) 680.87 — Outstanding as of September 30, 2023 448,676 (1) 10.34 4.2 Exercisable as of September 30, 2023 194,878 30.92 3.9 (1) Includes options related to 99,000 shares that are inducement awards and not granted under the 2018 Plan. The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 was $1.24 per share, based on the following assumptions used in the Black-Scholes option pricing model: Expected volatility 128 % Expected dividend yield — Expected term (in years) 5 Risk-free interest rate 5.3 % The expected volatility assumption is based on the calculated volatility of our common stock at the date of grant based on historical prices over the most recent period commensurate with the term of the award. The expected dividend yield assumption is based on our history and expected dividend payouts: we have not, and do not expect to, pay dividends. The expected term assumption is the contractual term of the options for non-employees. The risk-free interest rate assumption is determined using the U.S. treasury yields for bonds with a maturity commensurate with the term of the award. Restricted Stock Units The following table presents the unvested restricted stock unit activity: Number of Weighted Unvested balance as of December 31, 2022 18,799 $ 2.71 Granted — — Vested (18,799) 2.71 Forfeited — — Unvested balance as of September 30, 2023 — — The stock-based compensation expense was recorded as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Research and development $ 5 $ 1 $ 12 $ 5 Selling, general and administrative (1) 165 139 455 565 Total stock-based compensation expense $ 170 $ 140 $ 467 $ 570 (1) Includes $44,000 and $100,000 related to stock issued in exchange for marketing services for the three and nine month periods ended September 30, 2023, respectively. The allocation between research and development and selling, general and administrative expense was based on the department and services performed by the employee or non-employee. At September 30, 2023, the total compensation cost related to unvested options not yet recognized was $382,000, which will be recognized over a weighted average period of 1.3 years, assuming the employees and non-employees complete their service period required for vesting.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY On August 18, 2023, at a special meeting of stockholders, our stockholders approved an amendment to our amended and restated certificate of incorporation, as amended, to effect a reverse stock split (the “Reverse Stock Split”) of our issued and outstanding common stock by a ratio of not less than 1-for-2 and not more than 1-for-12. The exact ratio of the Reverse Stock Split will be set within this range as determined by our board of directors in its sole discretion prior to the time of the Reverse Stock Split and will be publicly announced by us prior to the effective time. On July 21, 2023, our board of directors approved a public offering of shares of our common stock, together with Series D and Series E warrants to purchase shares of our common stock for aggregate gross proceeds of up to $7.5 million. See Form S-1 filed with the SEC on July 21, 2023 (File No. 333-273370). No shares have yet been issued pursuant to this filing. Activity in equity during the nine month periods ended September 30, 2023 and 2022 was as follows (dollars in thousands): Common Stock Additional Accumulated Total Shares Amount 2023 Balances as of December 31, 2022 809,648 $ 1 $ 127,481 $ (122,203) $ 5,279 Stock-based compensation — — 166 — 166 Issuance of common stock upon exercise of warrants 1,230,000 1 (1) — — Issuance of common stock for service 13,225 — 100 — 100 Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes 54,466 — (11) — (11) Net loss — — — (2,037) (2,037) Balances as of March 31, 2023 2,107,339 2 127,735 (124,240) 3,497 Stock-based compensation — — 113 — 113 Issuance of common stock, net of issuance costs 857,146 1 1,209 — 1,210 Net loss — — — (1,993) (1,993) Balances as of June 30, 2023 2,964,485 3 129,057 (126,233) 2,827 Stock-based compensation — — 88 — 88 Modification of terms related to certain warrants — — 657 657 Issuance of common stock upon exercise of warrants, net 315,000 — 1,131 — 1,131 Net loss — — — (1,947) (1,947) Balances as of September 31, 2023 3,279,485 3 $ 130,933 $ (128,180) $ 2,756 2022 Balances as of December 31, 2021 610,364 1 $ 122,542 $ (112,508) $ 10,035 Stock-based compensation — — 221 — 221 Issuance of common stock for service 250 — 3 — 3 Net loss — — — (2,332) (2,332) Balances as of March 31, 2022 610,614 1 122,766 (114,840) 7,927 Stock-based compensation — — 205 — 205 Issuance of common stock for service 34 — 1 — 1 Net loss — — — (2,569) (2,569) Balances as of June 30, 2022 610,648 1 122,972 (117,409) 5,564 Stock-based compensation — — 139 — 139 Net loss — — — (2,646) (2,646) Balances as of September 30, 2022 610,648 1 $ 123,111 $ (120,055) $ 3,057 During the nine months ended September 30, 2023, the following shares of common stock were issued: • 315,000 shares pursuant to the exercise of warrants. A certain warrant holder was induced to exercise warrants related to 2,934,575 shares by reducing the exercise price to the then current market price of our common stock (the “Warrant Inducement”). The original warrants had an exercise price of $3.165 per share and a weighted average remaining life of 2.3 years. These warrants were exercised for $0.7202 per share for gross proceeds of $2.1 million, before deducting $326,000 of issuance costs and $657,000 related to the modification of the terms of the warrants to induce exercise. Of the 2,934,575 shares issued, 2,619,575 shares are held in abeyance and not considered outstanding, at which time such shares will become outstanding. The balance of the shares held in abeyance will be held in abeyance until notice from the stock holder that the balance, or portion thereof, may be issued in compliance with a beneficial ownership limitation provision in the warrants. See Note 10 for a discussion of outstanding abeyance shares. In connection with the Warrant Inducement transaction, new warrants to purchase 5,869,150 shares of our common stock were issued, which are discussed in Note 7. • 857,146 shares pursuant to a registered direct offering with certain institutional investors for $1.75 per share for gross proceeds of $1.5 million, before deducting issuance costs of $290,000. The shares were offered and sold pursuant to a prospectus, dated May 6, 2022, and a prospectus supplement, dated April 10, 2023, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-261227). • 1,230,000 shares pursuant to the exercise of previously outstanding prefunded warrants, which were issued in November 2022 with an exercise price of $1.54 per share. • 54,466 restricted shares in exchange for marketing services to be performed through September 2023, with the total value of services to be recognized based on the stock price on the date of issuance. • 13,225 shares pursuant to the vesting of restricted stock units. The following table presents the common stock warrant activity: Shares Weighted Weighted Outstanding as of December 31, 2022 4,414,810 $ 6.58 3.0 Issued 6,937,311 0.88 4.9 Exercised (4,164,575) 1.54 — Expired (13,629) 527.05 — Outstanding as of September 30, 2023 7,173,917 2.00 4.9 During the nine months ended September 30, 2023: • In August, warrants were issued to the investor in the Warrant Inducement transaction discussed in Note 6 to purchase up to 5,869,150 shares of our common stock. These warrants are exercisable immediately with an exercise price of $0.7202 per share, and 3,012,006 expiring August 24, 2028 (5-Year Warrants) and 2,857,144 expiring September 24, 2024 (13-Month Warrants). We estimated the fair value of the 5-Year Warrants to be $1.5 million using a Black-Scholes model based on the following significant inputs: common stock price of $0.682 per share; volatility of 98%; term of 5 years; dividend yield of 0%; and risk-free rate of 4.4%. The fair value of the 13-Month Warrants was estimated to be $930,000 using the Black-Scholes model based on the following significant inputs: common stock price of $0.682 per share; volatility of 122%; term of 1.1 year; dividend yield of 0%; and risk-free rate of 4.4%. • In August, placement agent warrants were issued to purchase up to 146,729 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $0.9003 per share, and expire August 24, 2028. We estimated the fair value of these warrants to be $72,000 using a Black-Scholes model based on the following significant inputs: common stock price of $0.682 per share; volatility of 98%; term of 5 years; dividend yield of 0%;and risk-free interest rate of 5.4%. • In August, warrants representing 2,934,575 shares of common stock were exercised for $0.7202 per share. The terms of these warrants were modified in order to induce exercise. See Warrant Inducement discussion in Note 6. We recorded additional equity costs of $657,000 related to the warrant exercise transaction, which was calculated as the difference between the fair value of the warrants immediately prior to modification and immediately after modification using the Black-Scholes model based on the following significant inputs: common stock price of $0.682 per share; volatility of 96%; term of 2.3 years; dividend yield of 0%; and risk-free rate of 5.0%. • In April, Series C warrants were issued to the investors in the offering discussed in Note 6 to purchase up to 857,146 shares of our common stock. The Series C warrants are exercisable immediately with an exercise price of $1.62 per share and expire October 12, 2028. We estimated the fair value of these warrants to be $1.1 million using a Black-Scholes model based on the following significant inputs: common stock price of $1.38 per share; volatility of 164%; term of 5.5 years; dividend yield of 0%; and risk-free interest rate of 3.4%. • In April, placement agent warrants were issued to purchase up to 64,286 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $2.1875 per share, and expire April 10, 2028. We estimated the fair value of these warrants to be $82,000 using a Black-Scholes model based on the following significant inputs: common stock price of $1.38 per share; volatility of 165%; term of 5 years; dividend yield of 0%;and risk-free interest rate of 3.5%. • In February, prefunded warrants representing 1,230,000 shares of common stock were exercised. Such prefunded warrants were issued in November 2022 with an exercise price of $1.54 per share.

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
COMMON STOCK WARRANTS	STOCKHOLDERS’ EQUITY On August 18, 2023, at a special meeting of stockholders, our stockholders approved an amendment to our amended and restated certificate of incorporation, as amended, to effect a reverse stock split (the “Reverse Stock Split”) of our issued and outstanding common stock by a ratio of not less than 1-for-2 and not more than 1-for-12. The exact ratio of the Reverse Stock Split will be set within this range as determined by our board of directors in its sole discretion prior to the time of the Reverse Stock Split and will be publicly announced by us prior to the effective time. On July 21, 2023, our board of directors approved a public offering of shares of our common stock, together with Series D and Series E warrants to purchase shares of our common stock for aggregate gross proceeds of up to $7.5 million. See Form S-1 filed with the SEC on July 21, 2023 (File No. 333-273370). No shares have yet been issued pursuant to this filing. Activity in equity during the nine month periods ended September 30, 2023 and 2022 was as follows (dollars in thousands): Common Stock Additional Accumulated Total Shares Amount 2023 Balances as of December 31, 2022 809,648 $ 1 $ 127,481 $ (122,203) $ 5,279 Stock-based compensation — — 166 — 166 Issuance of common stock upon exercise of warrants 1,230,000 1 (1) — — Issuance of common stock for service 13,225 — 100 — 100 Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes 54,466 — (11) — (11) Net loss — — — (2,037) (2,037) Balances as of March 31, 2023 2,107,339 2 127,735 (124,240) 3,497 Stock-based compensation — — 113 — 113 Issuance of common stock, net of issuance costs 857,146 1 1,209 — 1,210 Net loss — — — (1,993) (1,993) Balances as of June 30, 2023 2,964,485 3 129,057 (126,233) 2,827 Stock-based compensation — — 88 — 88 Modification of terms related to certain warrants — — 657 657 Issuance of common stock upon exercise of warrants, net 315,000 — 1,131 — 1,131 Net loss — — — (1,947) (1,947) Balances as of September 31, 2023 3,279,485 3 $ 130,933 $ (128,180) $ 2,756 2022 Balances as of December 31, 2021 610,364 1 $ 122,542 $ (112,508) $ 10,035 Stock-based compensation — — 221 — 221 Issuance of common stock for service 250 — 3 — 3 Net loss — — — (2,332) (2,332) Balances as of March 31, 2022 610,614 1 122,766 (114,840) 7,927 Stock-based compensation — — 205 — 205 Issuance of common stock for service 34 — 1 — 1 Net loss — — — (2,569) (2,569) Balances as of June 30, 2022 610,648 1 122,972 (117,409) 5,564 Stock-based compensation — — 139 — 139 Net loss — — — (2,646) (2,646) Balances as of September 30, 2022 610,648 1 $ 123,111 $ (120,055) $ 3,057 During the nine months ended September 30, 2023, the following shares of common stock were issued: • 315,000 shares pursuant to the exercise of warrants. A certain warrant holder was induced to exercise warrants related to 2,934,575 shares by reducing the exercise price to the then current market price of our common stock (the “Warrant Inducement”). The original warrants had an exercise price of $3.165 per share and a weighted average remaining life of 2.3 years. These warrants were exercised for $0.7202 per share for gross proceeds of $2.1 million, before deducting $326,000 of issuance costs and $657,000 related to the modification of the terms of the warrants to induce exercise. Of the 2,934,575 shares issued, 2,619,575 shares are held in abeyance and not considered outstanding, at which time such shares will become outstanding. The balance of the shares held in abeyance will be held in abeyance until notice from the stock holder that the balance, or portion thereof, may be issued in compliance with a beneficial ownership limitation provision in the warrants. See Note 10 for a discussion of outstanding abeyance shares. In connection with the Warrant Inducement transaction, new warrants to purchase 5,869,150 shares of our common stock were issued, which are discussed in Note 7. • 857,146 shares pursuant to a registered direct offering with certain institutional investors for $1.75 per share for gross proceeds of $1.5 million, before deducting issuance costs of $290,000. The shares were offered and sold pursuant to a prospectus, dated May 6, 2022, and a prospectus supplement, dated April 10, 2023, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-261227). • 1,230,000 shares pursuant to the exercise of previously outstanding prefunded warrants, which were issued in November 2022 with an exercise price of $1.54 per share. • 54,466 restricted shares in exchange for marketing services to be performed through September 2023, with the total value of services to be recognized based on the stock price on the date of issuance. • 13,225 shares pursuant to the vesting of restricted stock units. The following table presents the common stock warrant activity: Shares Weighted Weighted Outstanding as of December 31, 2022 4,414,810 $ 6.58 3.0 Issued 6,937,311 0.88 4.9 Exercised (4,164,575) 1.54 — Expired (13,629) 527.05 — Outstanding as of September 30, 2023 7,173,917 2.00 4.9 During the nine months ended September 30, 2023: • In August, warrants were issued to the investor in the Warrant Inducement transaction discussed in Note 6 to purchase up to 5,869,150 shares of our common stock. These warrants are exercisable immediately with an exercise price of $0.7202 per share, and 3,012,006 expiring August 24, 2028 (5-Year Warrants) and 2,857,144 expiring September 24, 2024 (13-Month Warrants). We estimated the fair value of the 5-Year Warrants to be $1.5 million using a Black-Scholes model based on the following significant inputs: common stock price of $0.682 per share; volatility of 98%; term of 5 years; dividend yield of 0%; and risk-free rate of 4.4%. The fair value of the 13-Month Warrants was estimated to be $930,000 using the Black-Scholes model based on the following significant inputs: common stock price of $0.682 per share; volatility of 122%; term of 1.1 year; dividend yield of 0%; and risk-free rate of 4.4%. • In August, placement agent warrants were issued to purchase up to 146,729 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $0.9003 per share, and expire August 24, 2028. We estimated the fair value of these warrants to be $72,000 using a Black-Scholes model based on the following significant inputs: common stock price of $0.682 per share; volatility of 98%; term of 5 years; dividend yield of 0%;and risk-free interest rate of 5.4%. • In August, warrants representing 2,934,575 shares of common stock were exercised for $0.7202 per share. The terms of these warrants were modified in order to induce exercise. See Warrant Inducement discussion in Note 6. We recorded additional equity costs of $657,000 related to the warrant exercise transaction, which was calculated as the difference between the fair value of the warrants immediately prior to modification and immediately after modification using the Black-Scholes model based on the following significant inputs: common stock price of $0.682 per share; volatility of 96%; term of 2.3 years; dividend yield of 0%; and risk-free rate of 5.0%. • In April, Series C warrants were issued to the investors in the offering discussed in Note 6 to purchase up to 857,146 shares of our common stock. The Series C warrants are exercisable immediately with an exercise price of $1.62 per share and expire October 12, 2028. We estimated the fair value of these warrants to be $1.1 million using a Black-Scholes model based on the following significant inputs: common stock price of $1.38 per share; volatility of 164%; term of 5.5 years; dividend yield of 0%; and risk-free interest rate of 3.4%. • In April, placement agent warrants were issued to purchase up to 64,286 shares of our common stock. The placement agent warrants are exercisable immediately upon issuance, with an exercise price per share of $2.1875 per share, and expire April 10, 2028. We estimated the fair value of these warrants to be $82,000 using a Black-Scholes model based on the following significant inputs: common stock price of $1.38 per share; volatility of 165%; term of 5 years; dividend yield of 0%;and risk-free interest rate of 3.5%. • In February, prefunded warrants representing 1,230,000 shares of common stock were exercised. Such prefunded warrants were issued in November 2022 with an exercise price of $1.54 per share.

LOSS PER SHARE

LOSS PER SHARE	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
LOSS PER SHARE	LOSS PER SHARE Basic loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, which includes prefunded warrants and shares held in abeyance from date of issuance. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus potentially dilutive securities outstanding during the period determined using the treasury stock method. Stock options, warrants and restricted stock units are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share because their effect would be anti-dilutive given the net losses reported for all periods presented. Therefore, basic and diluted loss per share are the same for each period presented. The following shares were excluded from the calculation of diluted net loss per share: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Common stock warrants 259,380 — 3,277,507 — Stock options — — 42,825 10,170 Restricted stock units — — — — 259,380 — 3,320,332 10,170

CONTINGENCIES

CONTINGENCIES	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES Legal Proceedings In July 2020, our former corporate general counsel (the “Plaintiff”) commenced an action against us in the Superior Court of the State of California, for the County of San Diego. The complaint alleges, among other things, that we breached the Plaintiff’s employment contract with us, as well as the implied covenant of good faith and fair dealing, by refusing to issue him the balance of stock options he claims we owe him. In September 2021, the Plaintiff served us and also named 10 individuals as defendants, consisting of current and former directors and employees. We do not believe that all of the defendants have yet been served. Furthermore, two individually named defendants have separately settled with the Plaintiff. The Plaintiff alleges that such individuals agreed to knowingly and wrongfully withhold the stock options owed to him and are knowingly in receipt of stolen property. The Plaintiff seeks compensatory damages in excess of $500,000, treble damages, and reasonable attorneys’ fees. We do not believe the claims described above have merit and intend to aggressively defend against these accusations. The Plaintiff has agreed to mediation to resolve the issues. We do not believe that this litigation is likely to have a material effect on our operations.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTSIn connection with the Warrant Inducement discussed in Note 6, of the 2,934,575 shares issued, 2,619,575 shares were held in abeyance and not considered outstanding until certain conditions are met, at which time such shares will become outstanding. The balance of the shares in abeyance will be held in abeyance until notice from the stock holder that the balance, or potion thereof, may be issued in compliance with a beneficial ownership limitation provision in the warrants. In October 2023, the conditions were met and the stock holder provided notice to release 351,575 shares from abeyance which became outstanding. As of November 9, 2023, there were 3,631,060 shares of common stock outstanding and 2,268,000 shares held in abeyance. In November 2023, we launched our latest product, Evolve, a soft bait containing the active ingredient cottonseed oil. Evolve limits reproduction of male and female rats after one to two breeding cycles following consumption. Evolve is being marketed for use in controlling rat populations as a minimum risk pesticide under the U.S. Environmental Protection Agency Federal Insecticide, Fungicide, and Rodenticide Act, Section 25(b). We must obtain registration from the various state regulatory agencies that do not accept the federal exemption. To date, we are authorized to sell Evolve in 12 states. We have evaluated subsequent events from the balance sheet date through November 9, 2023, the date at which the condensed financial statements were issued, and determined that there were no additional items that require adjustment to or disclosure in the condensed financial statements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net loss	$ (1,947)	$ (1,993)	$ (2,037)	$ (2,646)	$ (2,569)	$ (2,332)	$ (5,977)	$ (7,547)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Financial Statements	Condensed Financial StatementsOur accompanying unaudited condensed financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with the U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In our opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly our financial position as of September 30, 2023, and our operating results and cash flows for the three- and nine-month periods ended September 30, 2023 and 2022.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our condensed financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in our financial statements include the valuation of inventory, common stock warrants, and stock-based awards, such as stock options and restricted stock units. Actual results could differ from such estimates.
Comprehensive Loss	Comprehensive Loss We have no other comprehensive income items for the periods presented. As a result, our net loss and comprehensive loss were the same for the periods presented and a separate statement of comprehensive loss is not included in the accompanying condensed financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents Highly liquid investments with maturities of three months or less as of the date of acquisition are classified as cash equivalents, of which we had $2.1 million and $4.8 million as of September 30, 2023 and December 31, 2022, respectively, included within cash and cash equivalents in the condensed balance sheets.

BALANCE SHEET COMPONENTS (Table

BALANCE SHEET COMPONENTS (Tables)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accounts receivable, net and activity in allowance for uncollectible accounts	Accounts receivable, net consisted of the following (in thousands): September 30, December 31, Accounts receivable $ 85 $ 119 Allowance for uncollectible accounts (2) (6) Accounts receivable, net $ 83 $ 113 The following was the activity in the allowance for uncollectible accounts (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Balance as of beginning of period $ 4 $ 12 $ 6 $ — Increase in provision 2 — 2 12 Amounts written off, less recoveries (4) (7) (6) (7) Balance as of end of period $ 2 $ 5 $ 2 $ 5
Schedule of inventory, net and activity in reserve for obsolescence	Inventory, net consisted of the following (in thousands): September 30, December 31, Raw materials $ 670 $ 772 Work in progress 5 — Finished goods 46 99 Total inventory 721 871 Less: reserve for obsolescence (18) (18) Inventory, net $ 703 $ 853 The following was the activity in the reserve for obsolescence (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Balance as of beginning of period $ 18 $ 22 $ 18 $ 29 Increase in reserve — — — — Amounts relieved — (3) — (10) Balance as of end of period $ 18 $ 19 $ 18 $ 19
Schedule of prepaid expenses	Prepaid expenses consisted of the following (in thousands): September 30, December 31, Software licenses 138 157 Professional services 95 41 Insurance 44 61 Patents 17 39 Marketing programs and conferences 6 74 Other 85 6 Total prepaid expenses $ 385 $ 378
Schedule of property and equipment, net	Property and equipment, net consisted of the following (in thousands): September 30, December 31, Research and development equipment $ 1,621 $ 1,558 Office and computer equipment 808 800 Autos 54 54 Furniture and fixtures 41 41 Leasehold improvements 119 119 Total in service 2,643 2,572 Accumulated depreciation and amortization (2,387) (2,283) Total in service, net 256 289 Construction in progress 57 5 Property and equipment, net $ 313 $ 294
Schedule of accrued expenses	Accrued expenses consisted of the following (in thousands): September 30, December 31, Compensation, severance and related benefits $ 521 $ 497 Legal services 135 36 Product warranty 15 18 Personal property and franchise tax — 6 Other — 3 Total accrued expenses $ 671 $ 560
Schedule of maturities of notes payable	As of September 30, 2023, future principal payments were as follows (in thousands): 2023 $ 3 2024 9 2025 10 2026 11 2027 12 Thereafter 8 Total principal payments 53 Less: current portion of note payable (9) Note payable, less current portion $ 44

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of components of lease cost	The components of lease cost were as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Operating lease cost $ 55 $ 55 $ 166 $ 167 Finance lease cost: Amortization of right-of-use asset $ — $ — $ — $ 27 Interest on lease liability — — — 1 Total finance lease cost $ — $ — $ — $ 28
Schedule of future minimum operating lease payments	As of September 30, 2023, maturities of operating lease liabilities were as follows (in thousands): 2023 $ 50 2024 186 Total operating lease payments 236 Less: imputed interest (10) Total operating lease liabilities $ 226

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of stock option activity	The following table presents the outstanding stock option activity: Number of Options Weighted Weighted Three months ended September 30, 2023: Outstanding as of June 30, 2023 479,426 $ 17.11 4.4 Granted — — — Exercised — — — Forfeited (30,750) 5.25 — Expired — — — Outstanding as of September 30, 2023 448,676 (1) 10.34 4.2 Nine months ended September 30, 2023: Outstanding as of December 31, 2022 280,810 17.00 3.9 Granted 199,421 1.25 5.0 Exercised — — — Forfeited (31,183) 17.97 — Expired (372) 680.87 — Outstanding as of September 30, 2023 448,676 (1) 10.34 4.2 Exercisable as of September 30, 2023 194,878 30.92 3.9 (1) Includes options related to 99,000 shares that are inducement awards and not granted under the 2018 Plan.
Schedule of fair value of options granted, assumptions	The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 was $1.24 per share, based on the following assumptions used in the Black-Scholes option pricing model: Expected volatility 128 % Expected dividend yield — Expected term (in years) 5 Risk-free interest rate 5.3 %
Schedule of restricted stock unit activity	The following table presents the unvested restricted stock unit activity: Number of Weighted Unvested balance as of December 31, 2022 18,799 $ 2.71 Granted — — Vested (18,799) 2.71 Forfeited — — Unvested balance as of September 30, 2023 — —
Schedule of stock-based compensation expense	The stock-based compensation expense was recorded as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Research and development $ 5 $ 1 $ 12 $ 5 Selling, general and administrative (1) 165 139 455 565 Total stock-based compensation expense $ 170 $ 140 $ 467 $ 570 (1) Includes $44,000 and $100,000 related to stock issued in exchange for marketing services for the three and nine month periods ended September 30, 2023, respectively.

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of stockholders' equity activity	Activity in equity during the nine month periods ended September 30, 2023 and 2022 was as follows (dollars in thousands): Common Stock Additional Accumulated Total Shares Amount 2023 Balances as of December 31, 2022 809,648 $ 1 $ 127,481 $ (122,203) $ 5,279 Stock-based compensation — — 166 — 166 Issuance of common stock upon exercise of warrants 1,230,000 1 (1) — — Issuance of common stock for service 13,225 — 100 — 100 Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes 54,466 — (11) — (11) Net loss — — — (2,037) (2,037) Balances as of March 31, 2023 2,107,339 2 127,735 (124,240) 3,497 Stock-based compensation — — 113 — 113 Issuance of common stock, net of issuance costs 857,146 1 1,209 — 1,210 Net loss — — — (1,993) (1,993) Balances as of June 30, 2023 2,964,485 3 129,057 (126,233) 2,827 Stock-based compensation — — 88 — 88 Modification of terms related to certain warrants — — 657 657 Issuance of common stock upon exercise of warrants, net 315,000 — 1,131 — 1,131 Net loss — — — (1,947) (1,947) Balances as of September 31, 2023 3,279,485 3 $ 130,933 $ (128,180) $ 2,756 2022 Balances as of December 31, 2021 610,364 1 $ 122,542 $ (112,508) $ 10,035 Stock-based compensation — — 221 — 221 Issuance of common stock for service 250 — 3 — 3 Net loss — — — (2,332) (2,332) Balances as of March 31, 2022 610,614 1 122,766 (114,840) 7,927 Stock-based compensation — — 205 — 205 Issuance of common stock for service 34 — 1 — 1 Net loss — — — (2,569) (2,569) Balances as of June 30, 2022 610,648 1 122,972 (117,409) 5,564 Stock-based compensation — — 139 — 139 Net loss — — — (2,646) (2,646) Balances as of September 30, 2022 610,648 1 $ 123,111 $ (120,055) $ 3,057

COMMON STOCK WARRANTS (Tables)

COMMON STOCK WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of common stock warrant activity	The following table presents the common stock warrant activity: Shares Weighted Weighted Outstanding as of December 31, 2022 4,414,810 $ 6.58 3.0 Issued 6,937,311 0.88 4.9 Exercised (4,164,575) 1.54 — Expired (13,629) 527.05 — Outstanding as of September 30, 2023 7,173,917 2.00 4.9

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of outstanding potentially dilutive securities	The following shares were excluded from the calculation of diluted net loss per share: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Common stock warrants 259,380 — 3,277,507 — Stock options — — 42,825 10,170 Restricted stock units — — — — 259,380 — 3,320,332 10,170

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) state territory	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of states registration received | state	50
Number of states approved removal of RUP designation | state	49
Number of major U.S. territories registration received | territory	5
Accumulated deficit	$ 128,180		$ 122,203
Cash and cash equivalents	2,145		$ 4,775
Loss on sale of property and equipment	0	$ 28
Proceeds received from sale of property and equipment	$ 0	$ 4

BALANCE SHEET COMPONENTS - Narr

BALANCE SHEET COMPONENTS - Narrative (Details) - USD ($) $ in Thousands	Aug. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents		$ 2,145	$ 4,775
Notes Payable
Debt Instrument [Line Items]
Debt, annual interest rate	9.10%
Debt, term	5 years

BALANCE SHEET COMPONENTS - Sche

BALANCE SHEET COMPONENTS - Schedule of accounts receivable, net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$ 85		$ 119
Allowance for uncollectible accounts	(2)	$ (4)	(6)	$ (5)	$ (12)	$ 0
Accounts receivable, net	$ 83		$ 113

BALANCE SHEET COMPONENTS - Sc_2

BALANCE SHEET COMPONENTS - Schedule of allowance for uncollectible accounts (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance as of beginning of period	$ 4	$ 12	$ 6	$ 0
Increase in provision	2	0	2	12
Amounts written off, less recoveries	(4)	(7)	(6)	(7)
Balance as of end of period	$ 2	$ 5	$ 2	$ 5

BALANCE SHEET COMPONENTS - Sc_3

BALANCE SHEET COMPONENTS - Schedule of inventory, net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 670		$ 772
Work in progress	5		0
Finished goods	46		99
Total inventory	721		871
Less: reserve for obsolescence	(18)	$ (18)	(18)	$ (19)	$ (22)	$ (29)
Inventory, net	$ 703		$ 853

BALANCE SHEET COMPONENTS - Sc_4

BALANCE SHEET COMPONENTS - Schedule of activity in reserve for obsolescence (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Inventory, Valuation Reserves [Roll Forward]
Balance as of beginning of period	$ 18	$ 22	$ 18	$ 29
Increase in reserve	0	0	0	0
Amounts relieved	0	(3)	0	(10)
Balance as of end of period	$ 18	$ 19	$ 18	$ 19

BALANCE SHEET COMPONENTS - Sc_5

BALANCE SHEET COMPONENTS - Schedule of prepaid expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Software licenses	$ 138	$ 157
Professional services	95	41
Insurance	44	61
Patents	17	39
Marketing programs and conferences	6	74
Other	85	6
Total prepaid expenses	$ 385	$ 378

BALANCE SHEET COMPONENTS - Sc_6

BALANCE SHEET COMPONENTS - Schedule of property and equipment, net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Accumulated depreciation and amortization	$ (2,387)	$ (2,283)
Property and equipment, net	313	294
Depreciable Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,643	2,572
Property and equipment, net	256	289
Research and development equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,621	1,558
Office and computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	808	800
Autos
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	54	54
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	41	41
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	119	119
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 57	$ 5

BALANCE SHEET COMPONENTS - Sc_7

BALANCE SHEET COMPONENTS - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation, severance and related benefits	$ 521	$ 497
Legal services	135	36
Product warranty	15	18
Personal property and franchise tax	0	6
Other	0	3
Total accrued expenses	$ 671	$ 560

BALANCE SHEET COMPONENTS - Sc_8

BALANCE SHEET COMPONENTS - Schedule of notes payable maturities (Details) - Notes Payable $ in Thousands	Sep. 30, 2023 USD ($)
Debt Instrument [Line Items]
2023	$ 3
2024	9
2025	10
2026	11
2027	12
Thereafter	8
Total principal payments	53
Less: current portion of note payable	(9)
Note payable, less current portion	$ 44

LEASES - Schedule of lease cost

LEASES - Schedule of lease cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Operating lease cost	$ 55	$ 55	$ 166	$ 167
Finance lease cost:
Amortization of right-of-use asset	0	0	0	27
Interest on lease liability	0	0	0	1
Total finance lease cost	$ 0	$ 0	$ 0	$ 28

LEASES - Schedule of maturities

LEASES - Schedule of maturities of operating leases liabilities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Leases [Abstract]
2023	$ 50
2024	186
Total operating lease payments	236
Less: imputed interest	(10)
Total operating lease liabilities	$ 226

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - 2018 Equity Incentive Plan - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2018	Jun. 26, 2023
Stock-Based Compensation (Details) [Line Items]
Shares authorized (in shares)			848,614
Common stock, available for issuance (in shares)	496,330
Unrecognized compensation cost	$ 382
Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, term		5 years
Weighted average grant date fair value (in dollars per share)	$ 1.24
Unrecognized compensation cost, period of recognition	1 year 3 months 18 days
Minimum | Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, vesting period		12 months
Maximum | Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, vesting period		36 months

STOCK-BASED COMPENSATION - Sche

STOCK-BASED COMPENSATION - Schedule of stock option activity (Details) - $ / shares	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Number of Options
Beginning Balance (in shares)	479,426	280,810	280,810
Granted (in shares)	0		199,421
Exercised (in shares)	0		0
Forfeited (in shares)	(30,750)		(31,183)
Expired (in shares)	0		(372)
Ending Balance (in shares)	448,676	479,426	448,676	280,810
Exercisable (in shares)	194,878		194,878
Weighted Average Exercise Price Per Share
Beginning Balance (in dollars per share)	$ 17.11	$ 17	$ 17
Granted (in dollars per share)	0		1.25
Exercised (in dollars per share)	0		0
Forfeited (in dollars per share)	5.25		17.97
Expired (in dollars per share)	0		680.87
Ending Balance (in dollars per share)	10.34	$ 17.11	10.34	$ 17
Exercisable (in dollars per share)	$ 30.92		$ 30.92
Weighted Average Remaining Contractual Term (years)
Outstanding	4 years 2 months 12 days	4 years 4 months 24 days	4 years 2 months 12 days	3 years 10 months 24 days
Granted			5 years
Exercisable			3 years 10 months 24 days
Stock Options, Inducement Awards
Number of Options
Ending Balance (in shares)	99,000		99,000

STOCK-BASED COMPENSATION - Sc_2

STOCK-BASED COMPENSATION - Schedule of fair value option assumptions (Details) - 2018 Equity Incentive Plan - Stock Options	9 Months Ended
	Sep. 30, 2023
Stock-Based Compensation (Details) [Line Items]
Expected volatility	128%
Expected dividend yield	0%
Expected term (in years)	5 years
Risk-free interest rate	5.30%

STOCK-BASED COMPENSATION - Sc_3

STOCK-BASED COMPENSATION - Schedule of restricted stock unit activity (Details) - Restricted Stock Units	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of Units
Beginning Balance (in shares) | shares	18,799
Granted (in shares) | shares	0
Vested (in shares) | shares	(18,799)
Forfeited (in shares) | shares	0
Ending Balance (in shares) | shares	0
Weighted Average Grant-Date Fair Value Per Unit
Beginning Balance (in dollars per share) | $ / shares	$ 2.71
Granted (in dollars per share) | $ / shares	0
Vested (in dollars per share) | $ / shares	2.71
Forfeited (in dollars per share) | $ / shares	0
Ending Balance (in dollars per share) | $ / shares	$ 0

STOCK-BASED COMPENSATION - Sc_4

STOCK-BASED COMPENSATION - Schedule of stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended					9 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	$ 170		$ 140			$ 467	$ 570
Issuance of common stock for service		$ 100		$ 1	$ 3
Research and development
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	5		1			12	5
Selling, general and administrative
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	165		$ 139			455	$ 565
Issuance of common stock for service	$ 44					$ 100

STOCKHOLDERS' EQUITY - Narrativ

STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)		1 Months Ended		3 Months Ended	9 Months Ended
	Jul. 21, 2023	Aug. 31, 2023	Feb. 28, 2023	Sep. 30, 2023	Sep. 30, 2023	Aug. 30, 2023
Stockholders’ Equity [Line Items]
Approved sale of stock, gross proceeds to be received (up to)	$ 7,500,000
Warrants, exercised (in shares)					4,164,575
Warrants, exercised (in dollars per share)				$ 1.54	$ 1.54
Modification of terms related to certain warrants				$ 657,000
Warrants, issued (in shares)					6,937,311
Issuance of common stock for service (in shares)					54,466
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes (in shares)					13,225
Series C, Registered Direct Offering
Stockholders’ Equity [Line Items]
Stock issuance costs					$ 290,000
Common stock sold (in shares)					857,146
Common stock sold, price per share (in dollars per share)				$ 1.75	$ 1.75
Common stock sold, gross proceeds					$ 1,500,000
Warrant Inducement Transaction
Stockholders’ Equity [Line Items]
Issuance of common stock upon exercise of warrants (in shares)					315,000
Warrant Inducement Transaction | Maximum
Stockholders’ Equity [Line Items]
Number of warrants (in shares)		5,869,150
Warrant Inducement Transaction, Modified
Stockholders’ Equity [Line Items]
Warrants, exercised (in shares)		2,934,575
Warrants, exercised (in dollars per share)		$ 0.7202				$ 3.165
Warrants, weighted average remaining life						2 years 3 months 18 days
Gross proceeds from exercise of warrants					$ 2,100,000
Stock issuance costs					$ 326,000
Modification of terms related to certain warrants				$ 657,000
Warrants, issued (in shares)		2,934,575
Warrants, issued, held in abeyance (in shares)		2,619,575
PreFunded Warrants, Issued in November 2022, Common Stock, Registered Direct Offering
Stockholders’ Equity [Line Items]
Issuance of common stock upon exercise of warrants (in shares)					1,230,000
Warrants, exercised (in shares)			1,230,000
Warrants, exercised (in dollars per share)			$ 1.54	$ 1.54	$ 1.54

STOCKHOLDERS' EQUITY - Activity

STOCKHOLDERS' EQUITY - Activity in stockholders' equity (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)			809,648				809,648
Beginning Balance	$ 2,827	$ 3,497	$ 5,279	$ 5,564	$ 7,927	$ 10,035	$ 5,279	$ 10,035
Stock-based compensation	88	113	166	139	205	221
Modification of terms related to certain warrants	657
Issuance of common stock upon exercise of warrants, net	1,131		0
Issuance of common stock for service (in shares)							54,466
Issuance of common stock for service			100		1	3
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes (in shares)							13,225
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes			(11)
Issuance of common stock, net of issuance costs		1,210
Net loss	$ (1,947)	(1,993)	(2,037)	(2,646)	(2,569)	(2,332)	$ (5,977)	(7,547)
Ending Balance (in shares)	3,279,485						3,279,485
Ending Balance	$ 2,756	$ 2,827	$ 3,497	$ 3,057	$ 5,564	$ 7,927	$ 2,756	$ 3,057
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)	2,964,485	2,107,339	809,648	610,648	610,614	610,364	809,648	610,364
Beginning Balance	$ 3	$ 2	$ 1	$ 1	$ 1	$ 1	$ 1	$ 1
Issuance of common stock upon exercise of warrants, net (in shares)	315,000	857,146	1,230,000
Issuance of common stock upon exercise of warrants, net		$ 1	$ 1
Issuance of common stock for service (in shares)			13,225		34	250
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes (in shares)			54,466
Ending Balance (in shares)	3,279,485	2,964,485	2,107,339	610,648	610,648	610,614	3,279,485	610,648
Ending Balance	$ 3	$ 3	$ 2	$ 1	$ 1	$ 1	$ 3	$ 1
Additional Paid-In Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	129,057	127,735	127,481	122,972	122,766	122,542	127,481	122,542
Stock-based compensation	88	113	166	139	205	221
Modification of terms related to certain warrants	657
Issuance of common stock upon exercise of warrants, net	1,131		(1)
Issuance of common stock for service			100		1	3
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes			(11)
Issuance of common stock, net of issuance costs		1,209
Ending Balance	130,933	129,057	127,735	123,111	122,972	122,766	130,933	123,111
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(126,233)	(124,240)	(122,203)	(117,409)	(114,840)	(112,508)	(122,203)	(112,508)
Net loss	(1,947)	(1,993)	(2,037)	(2,646)	(2,569)	(2,332)
Ending Balance	$ (128,180)	$ (126,233)	$ (124,240)	$ (120,055)	$ (117,409)	$ (114,840)	$ (128,180)	$ (120,055)

COMMON STOCK WARRANTS - Schedul

COMMON STOCK WARRANTS - Schedule of common stock warrant activity for the period (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Shares
Beginning Balance (in shares)	4,414,810
Issued (in shares)	6,937,311
Exercised (in shares)	(4,164,575)
Expired (in shares)	(13,629)
Ending Balance (in shares)	7,173,917	4,414,810
Weighted Average Exercise Price Per Share
Beginning Balance (in dollars per share)	$ 6.58
Issued (in dollars per share)	0.88
Exercised (in dollars per share)	1.54
Expired (in dollars per share)	527.05
Ending Balance (in dollars per share)	$ 2	$ 6.58
Weighted Average Remaining Contractual Term (years)
Outstanding (in years)	4 years 10 months 24 days	3 years
Issued (in years)	4 years 10 months 24 days

COMMON STOCK WARRANTS - Narrati

COMMON STOCK WARRANTS - Narrative (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	9 Months Ended
	Aug. 31, 2023 USD ($) $ / shares year shares	Feb. 28, 2023 $ / shares shares	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2023 $ / shares shares	Aug. 30, 2023 $ / shares	Apr. 30, 2023 USD ($) $ / shares year shares	Dec. 31, 2022 $ / shares
Class of Warrant or Right [Line Items]
Warrants, exercise price (in dollars per share)			$ 2	$ 2			$ 6.58
Warrants, exercised (in shares) | shares				4,164,575
Warrants, exercised (in dollars per share)			$ 1.54	$ 1.54
Modification of terms related to certain warrants | $			$ 657
Warrant Inducement Transaction
Class of Warrant or Right [Line Items]
Warrants, exercise price (in dollars per share)	$ 0.7202
Warrant Inducement Transaction | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	5,869,150
Warrant Inducement Transaction, 5-Year Warrant, Expires August 24, 2028
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	3,012,006
Warrants, term	5 years
Warrants, fair value | $	$ 1,500
Warrant Inducement Transaction, 5-Year Warrant, Expires August 24, 2028 | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.682
Warrant Inducement Transaction, 5-Year Warrant, Expires August 24, 2028 | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.98
Warrant Inducement Transaction, 5-Year Warrant, Expires August 24, 2028 | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year	5
Warrant Inducement Transaction, 5-Year Warrant, Expires August 24, 2028 | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
Warrant Inducement Transaction, 5-Year Warrant, Expires August 24, 2028 | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.044
Warrant Inducement Transaction, 13-Month Warrant, Expires September 24, 2024
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	2,857,144
Warrants, term	13 months
Warrants, fair value | $	$ 930
Warrant Inducement Transaction, 13-Month Warrant, Expires September 24, 2024 | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.682
Warrant Inducement Transaction, 13-Month Warrant, Expires September 24, 2024 | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	1.22
Warrant Inducement Transaction, 13-Month Warrant, Expires September 24, 2024 | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year	1.1
Warrant Inducement Transaction, 13-Month Warrant, Expires September 24, 2024 | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
Warrant Inducement Transaction, 13-Month Warrant, Expires September 24, 2024 | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.044
Common Stock, Warrants Issued To Placement Agent In August 2023 Offering
Class of Warrant or Right [Line Items]
Warrants, exercise price (in dollars per share)	$ 0.9003
Warrants, fair value | $	$ 72
Common Stock, Warrants Issued To Placement Agent In August 2023 Offering | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.682
Common Stock, Warrants Issued To Placement Agent In August 2023 Offering | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.98
Common Stock, Warrants Issued To Placement Agent In August 2023 Offering | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year	5
Common Stock, Warrants Issued To Placement Agent In August 2023 Offering | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
Common Stock, Warrants Issued To Placement Agent In August 2023 Offering | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.054
Common Stock, Warrants Issued To Placement Agent In August 2023 Offering | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares	146,729
Warrant Inducement Transaction, Modified
Class of Warrant or Right [Line Items]
Warrants, exercised (in shares) | shares	2,934,575
Warrants, exercised (in dollars per share)	$ 0.7202				$ 3.165
Modification of terms related to certain warrants | $			$ 657
Warrant Inducement Transaction, Modified | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.682
Warrant Inducement Transaction, Modified | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.96
Warrant Inducement Transaction, Modified | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year	2.3
Warrant Inducement Transaction, Modified | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0
Warrant Inducement Transaction, Modified | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input	0.050
April 2023 Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrants, exercise price (in dollars per share)						$ 1.62
Warrants, fair value | $						$ 1,100
April 2023 Registered Direct Offering | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input						1.38
April 2023 Registered Direct Offering | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input						1.64
April 2023 Registered Direct Offering | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year						5.5
April 2023 Registered Direct Offering | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input						0
April 2023 Registered Direct Offering | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input						0.034
April 2023 Registered Direct Offering | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares						857,146
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrants, exercise price (in dollars per share)						$ 2.1875
Warrants, fair value | $						$ 82
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input						1.38
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input						1.65
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input | year						5
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input						0
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants, fair value, measurement input						0.035
Common Stock, Warrants Issued to Placement Agent, April 2023, Registered Direct Offering | Maximum
Class of Warrant or Right [Line Items]
Number of warrants (in shares) | shares						64,286
PreFunded Warrants, Issued in November 2022, Common Stock, Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrants, exercised (in shares) | shares		1,230,000
Warrants, exercised (in dollars per share)		$ 1.54	$ 1.54	$ 1.54

LOSS PER SHARE -Schedule of out

LOSS PER SHARE -Schedule of outstanding potentially dilutive securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	259,380	0	3,320,332	10,170
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	259,380	0	3,277,507	0
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	0	0	42,825	10,170
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	0	0	0	0

CONTINGENCIES - Narrative (Deta

CONTINGENCIES - Narrative (Details) - Superior Court of the State of California, Kennan E. Kaedar Litigation - Pending Litigation	1 Months Ended
	Sep. 30, 2021 defendant	Jul. 31, 2020 USD ($)
Loss Contingencies [Line Items]
Number of defendants	10
Number of defendants, separately settled with plaintiff	2
Minimum
Loss Contingencies [Line Items]
Damages sought (in excess of) | $		$ 500,000

SUBSEQUENT EVENTS - Narrative (

SUBSEQUENT EVENTS - Narrative (Details)			1 Months Ended		9 Months Ended
	Nov. 09, 2023 shares	Nov. 09, 2023 state shares	Oct. 31, 2023 shares	Aug. 31, 2023 shares	Sep. 30, 2023 shares	Dec. 31, 2022 shares
Subsequent Event [Line Items]
Warrants, exercised (in shares)					4,164,575
Common stock, shares outstanding (in shares)					3,279,485	809,648
Warrant Inducement Transaction, Modified
Subsequent Event [Line Items]
Warrants, exercised (in shares)				2,934,575
Warrants, held in abeyance (in shares)				2,619,575
Subsequent Event
Subsequent Event [Line Items]
Warrants, held in abeyance (in shares)	2,268,000
Warrants, outstanding, released from abeyance (in shares)			351,575
Common stock, shares outstanding (in shares)	3,631,060	3,631,060
Subsequent Event | Evolve
Subsequent Event [Line Items]
Number of states authorized to sell product | state		12